184 related articles for article (PubMed ID: 23228386)
1. Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma.
Benitez A; Yates TJ; Shamaldevi N; Bowen T; Lokeshwar VB
J Urol; 2013 Jul; 190(1):285-90. PubMed ID: 23228386
[TBL] [Abstract][Full Text] [Related]
2. Growth inhibitory effect of an injectable hyaluronic acid-tyramine hydrogels incorporating human natural interferon-α and sorafenib on renal cell carcinoma cells.
Ueda K; Akiba J; Ogasawara S; Todoroki K; Nakayama M; Sumi A; Kusano H; Sanada S; Suekane S; Xu K; Bae KH; Kurisawa M; Igawa T; Yano H
Acta Biomater; 2016 Jan; 29():103-111. PubMed ID: 26481041
[TBL] [Abstract][Full Text] [Related]
3. Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib.
Roulin D; Waselle L; Dormond-Meuwly A; Dufour M; Demartines N; Dormond O
Mol Cancer; 2011 Jul; 10():90. PubMed ID: 21791089
[TBL] [Abstract][Full Text] [Related]
4. Novel combination therapy with imiquimod and sorafenib for renal cell carcinoma.
Karashima T; Komatsu T; Niimura M; Kawada C; Kamada M; Inoue K; Udaka K; Kuroda N; Shuin T
Int J Urol; 2014 Jul; 21(7):702-6. PubMed ID: 24571181
[TBL] [Abstract][Full Text] [Related]
5. Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model.
Kususda Y; Miyake H; Gleave ME; Fujisawa M
Br J Cancer; 2012 Jun; 106(12):1945-52. PubMed ID: 22588555
[TBL] [Abstract][Full Text] [Related]
6. Enhanced sensitivity to sorafenib by inhibition of Akt1 expression in human renal cell carcinoma ACHN cells both in vitro and in vivo.
Tei H; Miyake H; Fujisawa M
Hum Cell; 2015 Jul; 28(3):114-21. PubMed ID: 25862630
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines.
Tochizawa S; Masumori N; Yanai Y; Ohmoto Y; Yabuuchi Y; Tsukamoto T
Biomed Res; 2008 Dec; 29(6):271-8. PubMed ID: 19129670
[TBL] [Abstract][Full Text] [Related]
8. Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
Yuen JS; Sim MY; Sim HG; Chong TW; Lau WK; Cheng CW; Ong RW; Huynh H
Int J Oncol; 2012 Aug; 41(2):712-20. PubMed ID: 22641227
[TBL] [Abstract][Full Text] [Related]
9. High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.
Wang X; Zhang L; Goldberg SN; Bhasin M; Brown V; Alsop DC; Signoretti S; Mier JW; Atkins MB; Bhatt RS
J Transl Med; 2011 Dec; 9():220. PubMed ID: 22188900
[TBL] [Abstract][Full Text] [Related]
10. Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.
Martin B; Edeline J; Patard JJ; Oger E; Jouan F; Boulanger G; Zerrouki S; Vigneau C; Rioux-Leclercq N
J Cancer Res Clin Oncol; 2012 Jun; 138(6):907-16. PubMed ID: 22322364
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma.
Murakami M; Zhao S; Zhao Y; Chowdhury NF; Yu W; Nishijima K; Takiguchi M; Tamaki N; Kuge Y
Int J Oncol; 2012 Nov; 41(5):1593-600. PubMed ID: 22965141
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of myeloid cell leukemia-1: Association with sorafenib-induced apoptosis in human mucoepidermoid carcinoma cells and tumor xenograft.
Yu HJ; Shin JA; Jung JY; Nam JS; Hong IS; Cho NP; Cho SD
Head Neck; 2015 Sep; 37(9):1326-35. PubMed ID: 25043125
[TBL] [Abstract][Full Text] [Related]
13. Preclinical activity of cobimetinib alone or in combination with chemotherapy and targeted therapies in renal cell carcinoma.
Zhang L; Xie D; Lei Y; Na A; Zhu L
Future Oncol; 2021 Aug; 17(23):3051-3060. PubMed ID: 33906367
[No Abstract] [Full Text] [Related]
14. Ubenimex attenuates acquired sorafenib resistance in renal cell carcinoma by inhibiting Akt signaling in a lipophagy associated mechanism.
Liu S; Gao M; Wang X; Ding S; Lv J; Gao D; Wang Z; Niu Z
Oncotarget; 2016 Nov; 7(48):79141-79153. PubMed ID: 27816967
[TBL] [Abstract][Full Text] [Related]
15. Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal Cell Cancer Cells.
Yu X; Liu F; Zeng L; He F; Zhang R; Yan S; Zeng Z; Shu Y; Zhao C; Wu X; Lei J; Zhang W; Yang C; Wu K; Wu Y; An L; Huang S; Ji X; Gong C; Yuan C; Zhang L; Feng Y; Huang B; Liu W; Zhang B; Dai Z; Wang X; Liu B; Haydon RC; Luu HH; Gan H; He TC; Chen L
Cell Physiol Biochem; 2018; 47(3):957-971. PubMed ID: 29843133
[TBL] [Abstract][Full Text] [Related]
16. Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.
Hsu C; Lin LI; Cheng YC; Feng ZR; Shao YY; Cheng AL; Ou DL
Clin Cancer Res; 2016 May; 22(10):2555-64. PubMed ID: 26603262
[TBL] [Abstract][Full Text] [Related]
17. Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus.
Matsuki M; Adachi Y; Ozawa Y; Kimura T; Hoshi T; Okamoto K; Tohyama O; Mitsuhashi K; Yamaguchi A; Matsui J; Funahashi Y
Cancer Sci; 2017 Apr; 108(4):763-771. PubMed ID: 28107584
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological inhibitor of fatty acid synthase suppresses growth and invasiveness of renal cancer cells.
Horiguchi A; Asano T; Asano T; Ito K; Sumitomo M; Hayakawa M
J Urol; 2008 Aug; 180(2):729-36. PubMed ID: 18555493
[TBL] [Abstract][Full Text] [Related]
19. MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib.
Zheng B; Zhu H; Gu D; Pan X; Qian L; Xue B; Yang D; Zhou J; Shan Y
Biochem Biophys Res Commun; 2015 Apr; 459(2):234-239. PubMed ID: 25712526
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model.
Yuen JS; Sim MY; Siml HG; Chong TW; Lau WK; Cheng CW; Huynh H
Br J Cancer; 2011 Mar; 104(6):941-7. PubMed ID: 21407223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
